Edward Faber, DO on ENDURANCE Phase III Trial: Does this Change the Standard of Care? #ASCO2020 #ASCO

Edward A. Faber, DO, MS on carfilzomib, lenalidomide, and dexamethasone vs. bortezomib, lenalidomide, and dexamethasone for initial therapy of newly diagnosed multiple myeloma: results of ENDURANCE (E1A11) phase III trial.

Read here: https://meetinglibrary.asco.org/record/186906/abstract